Biology Reference
In-Depth Information
design and coordination, and helped to draft the manuscript. JL conceived the
study, participated in its design and coordination, and helped to draft the manu-
script.
references
1. Maiese K, Li F, Chong ZZ: New avenues of exploration for erythropoietin.
JAMA 2005, 293:90-95.
2. Parsa C, Matsumoto A, Kim J, Riel RU, Pascal LS, Walton GB, Thompson
RB, Petrofski JA, Annex BH, Stamler JS, Koch WJ: A novel protective effect of
erythropoietin in the infracted heart. J Clin Invest 2003, 112:999-1007.
3. Calvillo L, Latini R, Kajstura J, Leri A, Anversa P, Ghezzi P, Salio M, Cerami A,
Brines M: Recombinant human erythropoietin protects the myocardium from
ischemia-reperfusion injury and promotes beneficial remodeling. Proc Natl
Acad Sci USA 2003, 100:4802-4806.
4. Tramontano AF, Muniyappa R, Black AD, Blendea MC, Cohen I, Deng L,
Sowers JR, Cutaia MV, El-Sherif N: Erythropoietin protects cardiac myocytes
from hypoxia-induced apoptosis through an Akt-dependent pathway. Biochem
Biophys Res Comm 2003, 308:990-994.
5. Cai Z, Semenza GL: Phosphatidylinositol-3 kinase signaling is required for
erythropoietin-mediated acute protection against myocardial ischemia/reperfu-
son injury. Circulation 2004, 109:2050-2053.
6. Ribatti D, Vacca A, Roccaro AM, Crivellato E, Presta M: Erythropoietin as an
angiogenic factor. Eur J Clin Invest 2003, 33:891-896.
7. Heeschen C, Aicher A, Lehmann R, Fichtlscherer S, Vasa M, Urbich C,
Mildner-Rihm C, Martin H, Zeiher A, Dimmeler S: Erythropoietin is a potent
physiologic stimulus for endothelial progenitor cell mobilization. Blood 2003,
102:1340-1346.
8. Rao SV, Stamler JS: Erythropoietin, anemia, and orthostatic hypotension: the
evidence mounts. Clin Auton Res 2002, 12:141-143.
9. Lipsic E, Schoemaker RG, Meer P, Voors AA, vanVeldhuisen D, vanGilst WH:
Protective effects of erythropoietin in cardiac ischemia. From bench to bedside.
J Am Coll Cardiol 2006, 48:2161-2167.
10. Besarab A, Bolton WK, Browne KF, Egrie JC, NIssenson AR, Okamoto DM,
Schwab SJ, Goodkin DA: The effects of normal as compared with low hemat-
ocrit values in patients with cardiac disease who are receiving hemodialysis and
epoetin. N Engl J Med 1998, 339:584-590.
Search WWH ::




Custom Search